Market Overview

Global Orthobiologics Market size was valued at around 6.40 billion in 2023 and is expected to reach a value of USD 10.27 billion by 2032, at a CAGR of 5.9% over the forecast period (2024–2032).

The global market for orthobiologics is expanding at a quicker rate, driven by the rising demand for sophisticated remedies in orthopaedic treatment. Orthobiologics are bio-derived products that speed up musculoskeletal injury rehabilitation like bones, joints, ligaments, and tendons. All these products like bone grafts, stem cells, growth factors, and other biologic drugs are intended to enhance natural processes of healing, reduce recovery time, and enhance outcomes for patients. Orthobiologics have extensive uses in various conditions like spinal fusion, fracture fixation, sports medicine conditions, and osteoarthritis therapy.

Key drivers for the growth in the orthobiologics market are a higher incidence of musculoskeletal diseases, the ageing population of the world, and advances in biotechnology. Musculoskeletal disorders such as arthritis and fractures account for the predominant causes of disability in the world. The global ageing population also contributed to these cases of the disease since aged individuals are vulnerable to degenerative disease as well as injury. Higher injury rates in sporting activities and a fit lifestyle among young people have also been generating a consistent demand for innovative treatments.

Technological progress and research into regenerative medicine are also driving the orthobiologics market. Stem cell therapy, delivery systems for growth factors, and 3D printing technology advancements have opened the door to more efficient and individualized therapies. Biologic medicines are increasingly being engineered to replicate natural tissue, enable healing, and reduce complications of conventional orthopaedic surgery. All these are driving greater uptake of orthobiologics among healthcare practitioners and consumers themselves.

A second significant market driver is rising demand for minimally invasive treatments. Orthobiologics are increasingly used also in conjunction with these techniques to build maximum results with minimal tissue destruction and healing time. The shift to value-based care also boosted demand for low-cost, evidence-based treatment, propelling the use of orthobiologics.

But the orthobiologics sector is faced with issues such as the exorbitant cost of product development, regulatory demands that are of strict nature, and reimbursement issues. Despite these issues, the sector continues to experience high R&D investment as well as strategic collaborations between biotech firms, academia, and healthcare organizations.

Key Findings:

• In February 2022, Opus BA, a bone graft substitute for lumbar and cervical spine fusion procedures, was launched by Orthofix Medical Inc. Opus BA is designed to graft bone defects or holes that are not part of the integrity of the bony structure in the skeletal system. It is available in putty and strip forms.

Market Drivers

Increasing Prevalence of Musculoskeletal Disorders

• The increasing prevalence of musculoskeletal conditions is a key growth driver for the orthobiologics market. Osteoarthritis, rheumatoid arthritis, and fractures are becoming more common as populations age and lifestyles become more sedentary. Because these conditions impair mobility and quality of life, demand is growing for new treatments like orthobiologics that allow natural healing and reduce recovery time. This trend is also supported by the increasing prevalence of sport injuries, which are creating the demand for effective therapies in young and active population.

Advancements in Regenerative Medicine

• Advances in regenerative medicine are a major propeller of the market. Growth factors, tissue-engineered products, and stem cell therapy are new products that are revolutionizing orthopaedic care. The products enable more specific and effective treatment mechanisms with improved patient results. As research work continues in biologic materials, the market is witnessing the development of products with the capability to replicate natural tissue and accelerate the healing process.

Market Opportunities

Rising Demand for Minimally Invasive Procedures

• The increasing need for minimally invasive procedures is a major opportunity for the orthobiologics market. Minimally invasive procedures are more and more favoured by patients because they have shorter recovery times, less post-operative pain, and fewer complications. Orthobiologics supplement minimally invasive methods by promoting tissue regeneration and enhancing overall results, and thus become a part of contemporary orthopaedic treatment. With changing surgical practices, the use of orthobiologics in minimally invasive procedures is likely to increase.

Growth in Biologics R&D Investments

• The added investment in R&D on biologics is the main opportunity for the orthobiologics market. Biologics, which are derived from nature-based materials like cells, proteins, and tissues, are the frontier of regenerative medicine. Venture capitalists, private enterprise, and public organizations are pushing more investment, and that investment is pushing orthobiologic technologies such as biomaterials, growth factors, and stem cell therapies. These investments are allowing researchers to create innovative solutions that respond to key problems in orthopaedic care, including enhanced tissue regeneration, decreased recovery time, and better patient outcomes.
• R&D is also aimed at developing next-generation orthobiologic products that are safer, more efficient, and customized to the patient. For example, advances in bioengineering and three-dimensional printing (3D printing) are making it possible to design customized implants and biologics that resemble natural tissue. Moreover, the use of artificial intelligence (AI) and data analytics during R&D is expedited discovery and optimization of new biologic solutions.

Market Restraining Factors

High Development Costs of Orthobiologic Products

• High production costs of orthobiologic products are a major deterrent. Development, manufacture, and clinical trials of biologics are expensive. The costs are often transferred to end users, thus making products costly and out of reach, particularly in low- and middle-income countries. The complexity of development of biologics raises the financial risks for firms, reducing market expansion.

Stringent Regulatory Requirements

• Stringent regulatory mandates are another challenge of utmost importance. Orthobiologics would have to undergo extensive testing and approval procedures before they can ensure safety and effectiveness. This very time-consuming and expensive exercise would slow down entry into the marketplace of new products, deterring small firms and hindering innovation. In addition, regulatory infrastructure being disparate across regions makes life more complicated for manufacturers who have a global reach.

Segmentation Analysis

The market scope is segmented because of by Product, by Application, by End-use.

• By Product

Based on the Product of the market is segmented into Demineralized Bone Matrix (DBM), Allograft, Bone Morphogenetic Protein (BMP), Viscosupplementation, Synthetic Bone Substitutes, Stem Cell Therapy.

During 2023, the viscosupplementation segment led the market in terms of revenue share, with a near 41.0% lead. The trend is expected to be driven further by the increased number of new products launches as well as a rising number of patients suffering from osteoarthritis. Recent research entitled "Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050" discovered that the number of individuals with osteoarthritis increased by 132.2% since 1990, where around 595 million individuals all over the globe were diagnosed with it in the year 2020. As per the study, there would be a significant increase in cases of osteoarthritis of the knee, hand, hip, and others by the year 2050, with percentages being 74.9%, 48.6%, 78.6%, and 95.1%, respectively. Osteoarthritis is commonly treated through viscosupplementation via hyaluronic acid injection owing to its ease of use and high tolerance, which contributes to market growth.

The most rapidly growing segment in the forecast period is stem cell therapy. A conducive environment for the expansion of the stem cell therapy market has been created by the growing focus on personalised medicine and the overall increase in healthcare spending across the world. Furthermore, the stem cell therapy market has witnessed the introduction of new approaches and products due to advancements in biotechnology and regenerative medicine.

• By Application

Based on the Application of the market is segmented into Spinal Fusion, Trauma Repair, Reconstructive Surgery.

Since there is an increased prevalence of spine issues all over the world, the spinal fusion industry had the highest revenue market share in 2023 with about 49.9%. In the U.S., there are over 400,000 spinal fusion procedures performed annually, as stated by the ScienceDirect article. In addition, segmental growth is also being encouraged by the frequent penetration of bone morphogenetic proteins, demineralised bone matrices, autografts, and allografts in spinal fusion operations due to their ability to provide excellent bone stability and rapid bone healing. In addition, the market is increasing as a result of top companies' increasing interest in launching innovative bone-healing products. OssDsign AB made a strategic shift in November 2023 to focus on the orthobiologics sector in the United States. With this adjustment, OssDsign AB is presently a pure play orthobiologics company. The company will be centred around OssDsign Catalyst, a nanosynthetic bone graft product that has robust gross margins of 90% or more and is easily scalable. During spinal fusion surgery, OssDsign Catalyst, which is an over-the-counter drug, is employed to stimulate new bone growth.

During the forecast period, the reconstructive surgery segment of the market is likely to grow at a significant rate. The category is growing due to increasing demand for reconstructive surgery triggered by an ageing population and a surge in musculoskeletal disorders. According to the ISAPS Global Survey, plastic surgeons performed 11.2% more procedures in 2022. Globally, there were about 18.8 million non-surgical and 14.9 million surgical procedures performed, sustaining the 41.3% growth that has been witnessed in the last four years. Orthobiologics are utilized in reconstructive surgeries since they provide a promising means of enhancing bone healing, stimulating soft tissue repair, and restoring joint function.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America has led the international orthobiologics market because of a number of important reasons. The region has developed healthcare infrastructure, high healthcare expenditure, and extensive use of sophisticated medical technologies. The availability of prominent medical device companies and research centres also contributes to market domination in North America. In addition, an increasing incidence of musculoskeletal conditions, such as osteoarthritis and spinal trauma, and an expanding geriatric population base support the region's stronghold. North America's focus on minimally invasive procedures and increasing biologic treatment preference have also further entrenched its dominance. The United States, specifically, is at the forefront, with substantial investments in orthobiologics R&D and a supportive reimbursement environment for new treatments.

The Asia-Pacific market will be the most rapidly growing orthobiologics market. This is due to the fast-growing healthcare industry, growing investments in healthcare, and expanding awareness about the latest treatments. The Asia-Pacific region also boasts a high and aging population that is increasingly susceptible to musculoskeletal conditions, making a high demand for orthobiologic treatments. Emerging markets such as China and India, with their expanding middle-class population and enhanced access to healthcare, are fuelling the rapid growth in this region. The increasing popularity of sports and physical activities among younger populations further enhances the demand for orthobiologics in the Asia-Pacific. With healthcare infrastructure still enhancing, Asia-Pacific is poised to experience strong growth in the orthobiologics market.

List of Companies Profiled

• Medtronic Plc
• DePuy Synthes
• Zimmer Biomet
• Stryker Corporation
• Bioventus LLC
• Anika Therapeutics, Inc.
• Orthofix, Inc.
• Globus Medical
• Arthrex, Inc.
• Bone Biologics Corp.

Key Industry Developments

In September 2023, Globus Medical, Inc. merged with NuVasive, Inc. The intention of the merger is to offer patients and surgeons a wide range of musculoskeletal procedural options and enabling technologies.

In August 2021, HyLink is a new product launched by Seikagaku Corporation. It is an injectable viscosupplement that can be administered once to alleviate osteoarthritis of the knee. The product was launched in Taiwan and is being distributed by New Taipei City-based TCM Biotech International Corp.

Report Coverage

The report will cover the qualitative and quantitative data on the global Orthobiologics Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Orthobiologics Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Orthobiologics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Orthobiologics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Orthobiologics companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Orthobiologics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Orthobiologics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Orthobiologics Market valued?
• Which region has the largest share in 2024 for the global Orthobiologics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Orthobiologics Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Orthobiologics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: